Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
JAK2 R938Q Ruxolitinib childhood B-cell acute lymphoblastic leukemia resistant detail...
KMT2A rearrange N/A childhood B-cell acute lymphoblastic leukemia not applicable detail...
JAK1 rearrange N/A childhood B-cell acute lymphoblastic leukemia not applicable detail...
JAK2 rearrange N/A childhood B-cell acute lymphoblastic leukemia not applicable detail...
JAK3 rearrange N/A childhood B-cell acute lymphoblastic leukemia not applicable detail...
ABL1 rearrange N/A childhood B-cell acute lymphoblastic leukemia not applicable detail...
FGFR1 rearrange N/A childhood B-cell acute lymphoblastic leukemia not applicable detail...
FLT3 rearrange N/A childhood B-cell acute lymphoblastic leukemia not applicable detail...
JAK1 mutant N/A childhood B-cell acute lymphoblastic leukemia not applicable detail...
JAK2 mutant N/A childhood B-cell acute lymphoblastic leukemia not applicable detail...
JAK3 mutant N/A childhood B-cell acute lymphoblastic leukemia not applicable detail...
KMT2A rearrange Blinatumomab childhood B-cell acute lymphoblastic leukemia predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02228096 Phase II Tisagenlecleucel Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients Completed USA 0
NCT02435849 Phase II Tisagenlecleucel Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | AUS 2
NCT02808442 Phase I UCART19 Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia (PALL) Completed USA | GBR | FRA | ESP 0
NCT02877303 Phase II Cyclophosphamide + Dexamethasone + Doxorubicin + Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Blinatumomab + Cyclophosphamide + Dexamethasone + Doxorubicin + Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Blinatumomab + Inotuzumab ozogamicin Blinatumomab + Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Ofatumumab + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Rituximab + Vincristine Sulfate Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia Recruiting USA 0
NCT02981628 Phase II Inotuzumab ozogamicin Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia Active, not recruiting USA 1
NCT03605589 Phase I Blinatumomab + Pembrolizumab Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma Withdrawn USA 0
NCT03642626 Phase II Cyclophosphamide + Fludarabine + Tisagenlecleucel axicabtagene ciloleucel + Cyclophosphamide + Fludarabine MT2017-45: CAR-T Cell Therapy for Heme Malignancies Recruiting USA 0
NCT03913559 Phase II Inotuzumab ozogamicin Cytarabine + Hydrocortisone + Methotrexate Acetaminophen + Diphenhydramine + Methylprednisolone Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia Recruiting USA 0
NCT03959085 Phase III Dexamethasone + Doxorubicin + Methotrexate + Pegaspargase + Vincristine Sulfate Cyclophosphamide + Cytarabine + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Leucovorin + Mercaptopurine + Methotrexate + Vincristine Sulfate Inotuzumab ozogamicin Cytarabine + Daunorubicin + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Sulfate Cytarabine + Daunorubicin + Methotrexate + Pegaspargase + Prednisolone + Vincristine Sulfate Cyclophosphamide + Cytarabine + Methotrexate + Pegaspargase + Thioguanine + Vincristine Sulfate Inotuzumab ozogamicin + Methotrexate Methotrexate + Pegaspargase + Vincristine Sulfate Mercaptopurine + Methotrexate + Prednisolone + Vincristine Sulfate Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Recruiting USA | CAN | AUS 2
NCT05748171 Phase II Asparaginase + Dexamethasone + Mitoxantrone + Vincristine Sulfate Inotuzumab ozogamicin A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL Recruiting ITA | FRA | ESP | DEU | BEL | AUT 12